The AIT Austrian Institute of Technology, BioVendor and SCIENION today announced that the three companies will partner on the development of an in-vitro diagnostic test for colon cancer. The innovative test kit shall identify cancer at an early stage based on tumor autoantibody biomarkers.
Colon cancer is one of the most common cancers being the second most common cause of cancer in women and the third most common in men. At the same time colon cancer is the fourth common cause of cancer related death. Early detection of this disease increases both the therapeutic success and the chance of survival. Current diagnostic practice involves either uncomfortable invasive procedures or uses stool tests, the latter resulting in a high percentage of false-positive results. The collaboration between BioVendor, SCIENION and AIT aims to use biomarkers for the early detection and screening based on patients blood samples. In the project, AIT's proprietary biomarkers will be developed into an easy-to-use in-vitro diagnostic (IVD) test kit. The technology takes advantage of the fact that specific tumor autoantibodies can be detected in blood of cancer patients in a very early stage of tumor development.
Development of an in vitro test kit
The three companies will work closely together to develop the in-vitro diagnostic test for the global market. AIT provides their previously identified and patented biomarkers, specific for blood-based diagnosis of colon cancer. BioVendor, represented by its subsidiary company TestLine Clinical Diagnostics, will bring in its development expertise and distribution network. SCIENION contributes with its longstanding expertise in the microarray market and will be responsible for assay development and manufacturing using the company's high-quality microtiter plates (sciPLEXPLATES).
Martin Weber, Head of the business unit Molecular Diagnostics at AIT, said: "We are entering the cooperation with BioVendor and SCIENON extremely enthusiastic and we strongly believe that the newly formed consortium has the power to perfectly drive forward AITs breakthrough biomarker technologies into market-ready solutions."
"We share the excitement expressed by Martin. Early, cost-efficient and non-invasive diagnosis of colon cancer is a largely unmet medical need that presents the newly formed consortium with an attractive commercial opportunity", said Viktor Ružička, CEO of the BioVendor group.
Holger Eickhoff, CEO of SCIENION AG, commented: "We are very happy to expand our existing collaboration with BioVendor for this new project. Getting AIT with its proprietary biomarker panel on board as a third partner is the perfect match for the development of colon cancer IVD. Once established, our test kit has the potential for broad colon cancer screening applications."
Unlocking glioblastoma's immune suppression mechanism